Cell & Gene Therapy · Bioprocessing
MaxCyte revenue, results and funding
MaxCyte filed revenue of $33M for 2025.
Data updated Nov 20, 2026 · Back to the company report
$33MRevenue, 2025
−$44.6MNet income, 2025
$760kTotal raised
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $33M | −$44.6M | $202.5M | – | $1.8M | $9.2M | $20.8M | −$51.9M | $20.1M | $1.8M |
| 2024 | $38.6M | −$41.1M | $239.5M | – | $1.7M | $13.1M | $22.2M | −$51.2M | $27.9M | – |
| 2023 | $41.3M | −$37.9M | $268.3M | – | $3.7M | $14M | $23.8M | −$48.3M | $46.5M | – |
| 2022 | $44.3M | −$23.6M | $286.7M | – | $18.5M | $11.8M | $19.5M | −$27.4M | $11.1M | – |
| 2021 | $33.9M | −$19.1M | $284.1M | $0 | $3.8M | $8M | $15.4M | −$18.2M | $47.8M | – |
| 2020 | $26.2M | −$11.8M | $51.8M | $0 | $2.1M | $2.5M | $17.7M | −$11.1M | $18.8M | – |
| 2019 | $21.6M | −$12.9M | – | $0 | $1.3M | $1.8M | $17.6M | −$12.4M | – | – |
Sources: SEC
Rounds and grants
| Year | Round | Amount |
|---|---|---|
| 2016 | Venture | $760k |
Sources: funding announcements, SEC filings, grant registers
How to cite
MaxCyte, Financials. Alion, Nov 20, 2026. https://alion.io/company/maxcyte/financials
